全文获取类型
收费全文 | 2566371篇 |
免费 | 189180篇 |
国内免费 | 7523篇 |
专业分类
耳鼻咽喉 | 34238篇 |
儿科学 | 84931篇 |
妇产科学 | 71553篇 |
基础医学 | 360594篇 |
口腔科学 | 69557篇 |
临床医学 | 232834篇 |
内科学 | 510668篇 |
皮肤病学 | 62404篇 |
神经病学 | 211864篇 |
特种医学 | 99831篇 |
外国民族医学 | 736篇 |
外科学 | 385120篇 |
综合类 | 50229篇 |
现状与发展 | 5篇 |
一般理论 | 967篇 |
预防医学 | 194376篇 |
眼科学 | 56460篇 |
药学 | 187394篇 |
8篇 | |
中国医学 | 5152篇 |
肿瘤学 | 144153篇 |
出版年
2019年 | 20621篇 |
2018年 | 29278篇 |
2017年 | 22593篇 |
2016年 | 26228篇 |
2015年 | 29502篇 |
2014年 | 40444篇 |
2013年 | 60422篇 |
2012年 | 80224篇 |
2011年 | 84481篇 |
2010年 | 51004篇 |
2009年 | 49149篇 |
2008年 | 79021篇 |
2007年 | 83835篇 |
2006年 | 85568篇 |
2005年 | 81738篇 |
2004年 | 78703篇 |
2003年 | 75855篇 |
2002年 | 73142篇 |
2001年 | 128188篇 |
2000年 | 131000篇 |
1999年 | 109787篇 |
1998年 | 29610篇 |
1997年 | 26196篇 |
1996年 | 26427篇 |
1995年 | 27228篇 |
1994年 | 24932篇 |
1993年 | 23287篇 |
1992年 | 85058篇 |
1991年 | 81539篇 |
1990年 | 78736篇 |
1989年 | 76004篇 |
1988年 | 69403篇 |
1987年 | 67952篇 |
1986年 | 63500篇 |
1985年 | 60466篇 |
1984年 | 44884篇 |
1983年 | 37847篇 |
1982年 | 22370篇 |
1981年 | 19905篇 |
1979年 | 38890篇 |
1978年 | 27369篇 |
1977年 | 23164篇 |
1976年 | 21419篇 |
1975年 | 22757篇 |
1974年 | 26737篇 |
1973年 | 25330篇 |
1972年 | 23730篇 |
1971年 | 21933篇 |
1970年 | 20155篇 |
1969年 | 19407篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
Robert J. Motzer MD David F. McDermott MD Bernard Escudier MD Mauricio Burotto MD Toni K. Choueiri MD Hans J. Hammers MD PhD Philippe Barthélémy MD PhD Elizabeth R. Plimack MD Camillo Porta MD Saby George MD Thomas Powles MD Frede Donskov MD PhD Howard Gurney MD Christian K. Kollmannsberger MD Marc-Oliver Grimm MD Carlos Barrios MD Yoshihiko Tomita MD PhD Daniel Castellano MD Viktor Grünwald MD PhD Brian I. Rini MD M. Brent McHenry PhD Chung-Wei Lee MD PhD Jennifer McCarthy MA Flavia Ejzykowicz PhD Nizar M. Tannir MD 《Cancer》2022,128(11):2085-2097
32.
33.
34.
35.
36.
Brede H. Eschliman MPH Hongmai H. Pham MD PhD Amol S. Navathe MD PhD Karen M. Dale BSN MSN Julian Harris MD MBA 《Health services research》2023,58(Z3):311-317
Objective
The aim was to identify healthcare payment and financing reforms to promote health equity and ways that the Agency for Healthcare Research and Quality (AHRQ) may promote those reforms.Data Sources and Study Setting
AHRQ convened a payment and financing workgroup–the authors of this paper–as part of its Health Equity Summit held in July 2022. This workgroup drew from its collective experience with healthcare payment and financing reform, as well as feedback from participants in a session at the Health Equity Summit, to identify the evidence base and promising paths for reforms to promote health equity.Study Design
The payment and financing workgroup developed an outline of reforms to promote health equity, presented the outline to participants in the payment and financing session of the July 2022 AHRQ Health Equity Summit, and integrated feedback from the participants.Data Collection/Extraction Methods
This paper did not require novel data collection; the authors collected the data from the existing evidence base.Principal Findings
The paper outlines root causes of health inequity and corresponding potential reforms in five domains: (1) the differential distribution of resources between healthcare providers serving different communities, (2) scarcity of financing for populations most in need, (3) lack of integration/accountability, (4) patient cost barriers to care, and (5) bias in provider behavior and diagnostic tools.Conclusions
Additional research is necessary to determine whether the proposed reforms are effective in promoting health equity. 相似文献37.
38.
39.
Georg Prokop Benedikt Wiestler Daniel Hieber Fynn Withake Karoline Mayer Jens Gempt Claire Delbridge Friederike Schmidt-Graf Nicole Pfarr Bruno Märkl Jürgen Schlegel Friederike Liesche-Starnecker 《International journal of cancer. Journal international du cancer》2023,153(9):1658-1670
Intratumor heterogeneity is a main cause of the dismal prognosis of glioblastoma (GBM). Yet, there remains a lack of a uniform assessment of the degree of heterogeneity. With a multiscale approach, we addressed the hypothesis that intratumor heterogeneity exists on different levels comprising traditional regional analyses, but also innovative methods including computer-assisted analysis of tumor morphology combined with epigenomic data. With this aim, 157 biopsies of 37 patients with therapy-naive IDH-wildtype GBM were analyzed regarding the intratumor variance of protein expression of glial marker GFAP, microglia marker Iba1 and proliferation marker Mib1. Hematoxylin and eosin stained slides were evaluated for tumor vascularization. For the estimation of pixel intensity and nuclear profiling, automated analysis was used. Additionally, DNA methylation profiling was conducted separately for the single biopsies. Scoring systems were established to integrate several parameters into one score for the four examined modalities of heterogeneity (regional, cellular, pixel-level and epigenomic). As a result, we could show that heterogeneity was detected in all four modalities. Furthermore, for the regional, cellular and epigenomic level, we confirmed the results of earlier studies stating that a higher degree of heterogeneity is associated with poorer overall survival. To integrate all modalities into one score, we designed a predictor of longer survival, which showed a highly significant separation regarding the OS. In conclusion, multiscale intratumor heterogeneity exists in glioblastoma and its degree has an impact on overall survival. In future studies, the implementation of a broadly feasible heterogeneity index should be considered. 相似文献